Philip's recent experience includes involving in:
● Genor Biopharma's (6998.HK) acquisition of Eddingpharm via a reverse takeover and share swap, obtaining a whitewash waiver under the Hong Kong Takeovers Code; this transaction marks the first reverse takeover of an unprofitable biotechnology company (Chapter 18A listed company) listed in Hong Kong, laying the foundation for similar transactions in the market;
● An investor's acquisition of Blue Bottle Coffee from Nestlé;
● Goertek's investment for a major equity stake in Conant Optical (a Hong Kong-listed optical technology enterprise) through the subscription of new shares and purchase of existing shares;
● A prominent fund client's participation in the De-SPAC transaction of TECHSTARACQ-Z (a SPAC listed in Hong Kong);
● A family office's investment in Chongqing Terminus Technology Co., Ltd. (an artificial intelligence business company) as a private equity investor;
● China Jianyin's investment in Qiangyi Semiconductor;
● Alibaba's investment in Horizon Robotics (a Hong Kong-listed technology enterprise) as a cornerstone investor;
● CDB International's sale of a 29.99% equity interest in China New Town (a Hong Kong-listed real estate enterprise), structured to avoid triggering a mandatory general offer under the Takeovers Code;
● China Mobile's investment for a major equity stake in AsiaInfo Technologies (a Hong Kong-listed software enterprise), advising on obligations under the Hong Kong Takeovers Code and representing the client in consultations with the SFC;
● Xingda International's conditional voluntary partial offer under the Hong Kong Takeovers Code;
● Morgan Stanley Private Equity Asia's sale of a minority stake in IVD Medical Holding Limited (a Hong Kong-listed medical enterprise);
● Suchuang Gas Corporation Limited's privatization by way of a Scheme of Arrangement and delisting from the Hong Kong Stock Exchange;
● A capital injection by a subsidiary of CTG International into China Tourism Group
● An A-share listed company's bid to acquire the controlling equity stake in AMVIG Holdings Limited, making a mandatory general offer and privatization bid;
● The transfer of controlling interest in Hong Kong International Construction Investment Management Group Co., Limited (HKICIM), representing the controlling shareholder and the listed company in negotiations with Blackstone Group, which triggered a mandatory general offer under the Takeovers Code;
● Providing legal advice to HKICIM and HNA Group on multiple transactions with an aggregate consideration exceeding USD 3 billion, involving prominent counterparties such as Blackstone, Henderson Land Development, and Wheelock Properties;
● Advising Singamas Container Holdings Limited on its application to the Hong Kong SFC for a whitewash waiver under the Takeovers and Mergers Code in relation to a rights issue;
● Starlight Culture Entertainment Group Limited's issuance of consideration shares for the acquisition of SERENSIGHT INVESTMENT COMPANY LTD;
● HKICIM's issuance of consideration shares for the acquisition of shares in Shengshi Enterprise Limited;
● CGN Power Co., Ltd.'s major transaction involving the acquisition of assets from China General Nuclear Power Corporation (CGN) for approximately RMB 10 billion;
● Kunlun Energy's very substantial acquisition of PetroChina Kunlun Gas Co., Ltd. for over USD 2.3 billion;
● Conducting compliance analysis for the Hong Kong subsidiaries of renowned enterprises such as CNOOC, COFCO, Beijing Enterprises, Citychamp Dartong, Sunmi Technology, and Suzhou Ribo Life Science;
● Providing Hong Kong compliance advice to multiple Hong Kong listed companies;
● Top-up placings for Hong Kong-listed companies including Sino Biopharmaceutical Limited, China Agri-Industries Holdings Limited, Kunlun Energy, and Real Gold Mining Ltd.;
● Listing applications/projects for a Chapter 18A company, Haimayun, Silicon Magic Semiconductor, Ucard Group, Tong Ren Tang Healthcare, etc;
● The listings and global offerings on the Hong Kong Stock Exchange of Ridge Outdoor, Clarity Medical Group, Genor Biopharma, MSPEA's portfolio company Home Control, BOCOM International, VPower Group, China Resources Pharmaceutical Group, Everbright Securities, CGN Power, Bank of Tianjin, Postal Savings Bank of China (PSBC), Huishang Bank, Huatai Securities, GF Securities, Wynn Macau, and Yingde Gases;
● A syndicated M&A loan of the USD equivalent of RMB 335 million for MSPEA;
● A USD 189 million syndicated M&A loan for China Education Group;
● Multiple bank loans totalling USD 40 million for Zhongsheng Group Holdings;
● Over HKD 1 billion in share pledge financing for HNA Finance I;
● A HKD 300 million financing transaction for HKICIM
